123 related articles for article (PubMed ID: 22832712)
1. Phenotyping methods for determining HIV tropism and applications in clinical settings.
Raymond S; Delobel P; Izopet J
Curr Opin HIV AIDS; 2012 Sep; 7(5):463-9. PubMed ID: 22832712
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing to assess HIV tropism.
Swenson LC; Däumer M; Paredes R
Curr Opin HIV AIDS; 2012 Sep; 7(5):478-85. PubMed ID: 22832710
[TBL] [Abstract][Full Text] [Related]
3. HIV population genotypic tropism testing and its clinical significance.
Obermeier M; Symons J; Wensing AM
Curr Opin HIV AIDS; 2012 Sep; 7(5):470-7. PubMed ID: 22832711
[TBL] [Abstract][Full Text] [Related]
4. Performance of a clonal-based HIV-1 tropism phenotypic assay.
Asin-Milan O; Wei Y; Sylla M; Vaisheva F; Chamberland A; Tremblay CL
J Virol Methods; 2014 Aug; 204():53-61. PubMed ID: 24731927
[TBL] [Abstract][Full Text] [Related]
5. Current tests to evaluate HIV-1 coreceptor tropism.
Rose JD; Rhea AM; Weber J; Quiñones-Mateu ME
Curr Opin HIV AIDS; 2009 Mar; 4(2):136-42. PubMed ID: 19339953
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
[TBL] [Abstract][Full Text] [Related]
8. [HIV tropism assays when first CCR5-antagonist becomes available].
Soulié C; Calvez V
Med Mal Infect; 2008 Mar; 38 Suppl 1():S7-11. PubMed ID: 18455056
[TBL] [Abstract][Full Text] [Related]
9. Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.
Ceresola ER; Nozza S; Sampaolo M; Pignataro AR; Saita D; Ferrarese R; Ripa M; Deng W; Mullins JI; Boeri E; Tambussi G; Toniolo A; Lazzarin A; Clementi M; Canducci F
J Antimicrob Chemother; 2015 May; 70(5):1391-5. PubMed ID: 25608585
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.
Garrido C; Roulet V; Chueca N; Poveda E; Aguilera A; Skrabal K; Zahonero N; Carlos S; García F; Faudon JL; Soriano V; de Mendoza C
J Clin Microbiol; 2008 Mar; 46(3):887-91. PubMed ID: 18199789
[TBL] [Abstract][Full Text] [Related]
11. Determination of HIV-1 coreceptor tropism in clinical practise.
Foeglein A; Walter H
Eur J Med Res; 2007 Oct; 12(9):473-82. PubMed ID: 17933729
[TBL] [Abstract][Full Text] [Related]
12. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.
Poveda E; Alcamí J; Paredes R; Córdoba J; Gutiérrez F; Llibre JM; Delgado R; Pulido F; Iribarren JA; García Deltoro M; Hernández Quero J; Moreno S; García F
AIDS Rev; 2010; 12(3):135-48. PubMed ID: 20842202
[TBL] [Abstract][Full Text] [Related]
13. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage.
Raymond S; Delobel P; Mavigner M; Cazabat M; Souyris C; Encinas S; Bruel P; Sandres-Sauné K; Marchou B; Massip P; Izopet J
J Clin Virol; 2010 Feb; 47(2):126-30. PubMed ID: 20015684
[TBL] [Abstract][Full Text] [Related]
14. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.
Poveda E; Seclén E; González Mdel M; García F; Chueca N; Aguilera A; Rodríguez JJ; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2009 May; 63(5):1006-10. PubMed ID: 19261623
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of HIV coreceptor tropism.
Hoffmann C
Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718
[TBL] [Abstract][Full Text] [Related]
16. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.
Raymond S; Delobel P; Mavigner M; Cazabat M; Souyris C; Sandres-Sauné K; Cuzin L; Marchou B; Massip P; Izopet J
AIDS; 2008 Sep; 22(14):F11-6. PubMed ID: 18753930
[TBL] [Abstract][Full Text] [Related]
17. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
Seclén E; Garrido C; González Mdel M; González-Lahoz J; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1486-92. PubMed ID: 20427374
[TBL] [Abstract][Full Text] [Related]
18. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism.
Saliou A; Delobel P; Dubois M; Nicot F; Raymond S; Calvez V; Masquelier B; Izopet J;
Antimicrob Agents Chemother; 2011 Jun; 55(6):2831-6. PubMed ID: 21464245
[TBL] [Abstract][Full Text] [Related]
19. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.
Poveda E; Paredes R; Moreno S; Alcamí J; Córdoba J; Delgado R; Gutiérrez F; Llibre JM; García Deltoro M; Hernández-Quero J; Pulido F; Iribarren JA; García F
AIDS Rev; 2012; 14(3):208-17. PubMed ID: 22833064
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
